Invesco Ltd. Sells 28,325 Shares of Lyell Immunopharma, Inc. $LYEL

Invesco Ltd. cut its holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL - Free Report) by 7.0% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 378,880 shares of the company's stock after selling 28,325 shares during the quarter. Invesco Ltd. owned approximately 0.13% of Lyell Immunopharma worth $204,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Exchange Traded Concepts LLC boosted its holdings in shares of Lyell Immunopharma by 82.4% in the 1st quarter. Exchange Traded Concepts LLC now owns 246,349 shares of the company's stock valued at $133,000 after buying an additional 111,299 shares during the last quarter. Public Employees Retirement System of Ohio acquired a new stake in shares of Lyell Immunopharma during the fourth quarter valued at about $64,000. venBio Partners LLC acquired a new stake in shares of Lyell Immunopharma during the fourth quarter valued at about $4,545,000. Two Sigma Advisers LP lifted its stake in shares of Lyell Immunopharma by 143.8% in the fourth quarter. Two Sigma Advisers LP now owns 306,400 shares of the company's stock worth $196,000 after acquiring an additional 180,700 shares during the period. Finally, Millennium Management LLC lifted its stake in Lyell Immunopharma by 34.8% in the fourth quarter. Millennium Management LLC now owns 957,507 shares of the company's stock valued at $613,000 after buying an additional 247,440 shares during the period. Institutional investors own 66.05% of the company's stock.

Lyell Immunopharma Trading Down 3.6%

Shares of LYEL stock traded down $0.48 during trading hours on Friday, reaching $12.82. The company's stock had a trading volume of 32,402 shares, compared to its average volume of 23,871. Lyell Immunopharma, Inc. has a one year low of $7.65 and a one year high of $32.00. The stock has a market capitalization of $246.27 million, a P/E ratio of -0.53 and a beta of -0.19. The firm's fifty day simple moving average is $11.05 and its 200 day simple moving average is $10.34.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($2.89) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.80) by $0.91. Lyell Immunopharma had a negative return on equity of 85.58% and a negative net margin of 552,328.31%.The business had revenue of $0.01 million during the quarter, compared to analysts' expectations of $0.00 million. As a group, equities research analysts forecast that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Wall Street Zen raised Lyell Immunopharma from a "sell" rating to a "hold" rating in a research report on Monday, September 1st. HC Wainwright reiterated a "neutral" rating and set a $10.00 price target on shares of Lyell Immunopharma in a research note on Tuesday, June 24th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Lyell Immunopharma presently has a consensus rating of "Reduce" and a consensus price target of $15.00.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.